Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials

<p>OS between gefitinib and no gefitinib group in patients with advanced head and neck cancer (HR 1.07; Z=0.94; P=0.35).</p>

Journal of Oncology

fig3

Figure 3

Figure 3: Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials 

Figure 3 | Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials 